Literature DB >> 26375921

Parkinson's Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study.

Valentina Gallo1, Carol Brayne, Lars Forsgren, Roger A Barker, Jesper Petersson, Oskar Hansson, Daniel Lindqvist, Claudio Ruffmann, Lianna Ishihara, Robert Luben, Larraitz Arriola, Alberto Bergareche, Diana Gavrila, Maria Elena Erro, Nicola Vanacore, Carlotta Sacerdote, Bas Bueno-de-Mesquita, Roel Vermeulen, Meinie Seelen, Sabina Sieri, Giovanna Masala, Silvia Ramat, Andreas Kyrozis, Antonia Thricopolou, Salvatore Panico, Amalia Mattiello, Rudolf Kaaks, Birgit Teucher, Verena Katzke, Manja Kloss, Lisa Curry, Federico Calboli, Elio Riboli, Paolo Vineis, Lefkos Middleton.   

Abstract

BACKGROUND/AIMS: Large epidemiological prospective studies represent an important opportunity for investigating risk factors for rare diseases such as Parkinson's disease (PD). Here we describe the procedures we used for ascertaining PD cases in the EPIC (European Prospective Investigation into Cancer and Nutrition) study.
METHODS: The following three-phase procedure was used: (1) elaboration of a NeuroEPIC4PD template for clinical data collection, (2) identification of all potential PD cases via record linkage and (3) validation of the diagnosis through clinical record revision, in a population of 220,494 subjects recruited in 7 European countries. All cases were labelled with the NeuroEPIC4PD diagnoses of 'definite', 'very likely', 'probable', or 'possible' PD.
RESULTS: A total of 881 PD cases were identified, with over 2,741,780 person-years of follow-up (199 definite, 275 very likely, 146 probable, and 261 possible). Of these, 734 were incident cases. The mean age at diagnosis was 67.9 years (SD 9.2) and 458 patients (52.0%) were men. Bradykinesia was the most frequent presenting motor sign (76.5%). Tremor-dominant and akinetic rigid forms of PD were the most common types of PD. A total of 289 patients (32.8%) were dead at the time of the last follow-up.
CONCLUSIONS: This exercise proved that it is feasible to ascertain PD in large population-based cohort studies and offers a potential framework to be replicated in similar studies.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 26375921     DOI: 10.1159/000381857

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  6 in total

1.  A Set of Reliable Samples for the Study of Biomarkers for the Early Diagnosis of Parkinson's Disease.

Authors:  Marcela Konjevod; Jorge Sáiz; Coral Barbas; Alberto Bergareche; Eva Ardanaz; José Ma Huerta; Ana Vinagre-Aragón; Ma Elena Erro; Ma Dolores Chirlaque; Eunate Abilleira; Jesús Ma Ibarluzea; Pilar Amiano
Journal:  Front Neurol       Date:  2022-05-30       Impact factor: 4.086

2.  Parkinson's disease case ascertainment in prospective cohort studies through combining multiple health information resources.

Authors:  Marije Reedijk; Anke Huss; Robert A Verheij; Petra H Peeters; Roel C H Vermeulen
Journal:  PLoS One       Date:  2020-07-01       Impact factor: 3.240

3.  Exploring causality of the association between smoking and Parkinson's disease.

Authors:  Valentina Gallo; Paolo Vineis; Mariagrazia Cancellieri; Paolo Chiodini; Roger A Barker; Carol Brayne; Neil Pearce; Roel Vermeulen; Salvatore Panico; Bas Bueno-de-Mesquita; Nicola Vanacore; Lars Forsgren; Silvia Ramat; Eva Ardanaz; Larraitz Arriola; Jesper Peterson; Oskar Hansson; Diana Gavrila; Carlotta Sacerdote; Sabina Sieri; Tilman Kühn; Verena A Katzke; Yvonne T van der Schouw; Andreas Kyrozis; Giovanna Masala; Amalia Mattiello; Robert Perneczky; Lefkos Middleton; Rodolfo Saracci; Elio Riboli
Journal:  Int J Epidemiol       Date:  2019-06-01       Impact factor: 7.196

4.  Alcohol Consumption and Risk of Parkinson's Disease: Data From a Large Prospective European Cohort.

Authors:  Susan Peters; Valentina Gallo; Paolo Vineis; Lefkos T Middleton; Lars Forsgren; Carlotta Sacerdote; Sabina Sieri; Andreas Kyrozis; María-Dolores Chirlaque; Raul Zamora-Ros; Oskar Hansson; Jesper Petersson; Verena Katzke; Tilman Kühn; Olatz Mokoroa; Giovanna Masala; Eva Ardanaz; Salvatore Panico; Manuela M Bergmann; Timothy J Key; Elisabete Weiderpass; Pietro Ferrari; Roel Vermeulen
Journal:  Mov Disord       Date:  2020-05-01       Impact factor: 10.338

5.  Comparison of risk factors for Parkinson's disease, coronary events and ischemic stroke.

Authors:  Lu Song; Shunming Zhang; Huiping Li; Oskar Hansson; Emily Sonestedt; Yan Borné
Journal:  NPJ Parkinsons Dis       Date:  2022-08-25

6.  Identifying Parkinson's disease and parkinsonism cases using routinely collected healthcare data: A systematic review.

Authors:  Zoe Harding; Tim Wilkinson; Anna Stevenson; Sophie Horrocks; Amanda Ly; Christian Schnier; David P Breen; Kristiina Rannikmäe; Cathie L M Sudlow
Journal:  PLoS One       Date:  2019-01-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.